

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549




FORM 6-K

Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16 Under  
the Securities Exchange Act of 1934

August 27, 2002

**Forbes Medi-Tech Inc.**  
(Commission File No. 0-30076)

**200-750 West Pender Street**  
**Vancouver, British Columbia, Canada V6C 2T8**  
(Address of principal executive offices)



Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.  
Form 20-F  Form 40-F \_\_\_\_\_

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.  
Yes \_\_\_\_\_ No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): \_\_\_\_\_

**PROCESSED**  
**AUG 29 2002**  
**THOMSON**  
**FINANCIAL**

**Exhibit Index**

Exhibit No.

Description

1.

Press Release

August 27, 2002

**SIGNATURES**


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Forbes Medi-Tech Inc.

Date: August 27, 2002

By: \_\_\_\_\_

Charles Butt  
President & CEO

A handwritten signature in black ink, appearing to read "Charles A. Butt", is written over a horizontal line. The signature is stylized and cursive.

**Forbes Medi-Tech Announces Timing of Second Quarter Financial Results**


**Vancouver, British Columbia – August 27, 2002-** Forbes Medi-Tech Inc. (TSE:FMI and NASDAQ:FMTI) today announced that it will release its financial results for the second quarter ended June 30, 2002, following the close of markets on Thursday, August 29, 2002. A conference call and webcast to discuss these financial results will be held on September 4, 2002 at 1 p.m. PST. (4:00 p.m. EST).

**About the Conference Call and Webcast**

To participate in the conference call, please dial 416-695-9753 or 1-877-461-2814. For those investors unable to participate in the call, the live webcast can be accessed through the Company's website at [www.forbesmedi.com](http://www.forbesmedi.com). The call will also be available for replay until September 30, 2002 by calling 416-695-9731 or 1-888-509-0081. The webcast link will be archived on the Forbes website afterwards.

Forbes Medi-Tech Inc. is a biopharmaceutical company dedicated to the research, development and commercialization of innovative pharmaceuticals and nutraceutical products for the prevention and treatment of cardiovascular and related diseases. By extracting plant sterols from wood pulping by-products, Forbes has developed cholesterol-lowering agents to be used as pharmaceutical therapeutics, dietary supplements and functional food ingredients.

**ON BEHALF OF THE BOARD OF DIRECTORS OF FORBES MEDI-TECH INC.**



**Charles Butt**  
**President & CEO**

###

For more information, please contact:

Darren Seed  
Manager, Investor Relations  
Telephone: (604) 681-8976  
E-mail: [dseed@forbesmedi.com](mailto:dseed@forbesmedi.com)

*NASDAQ and the Toronto Stock Exchange have not reviewed and do not accept responsibility for the adequacy or accuracy of the content of this News Release. This press release contains certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act and Section 21E of the U.S. Securities Exchange Act of 1934, which statements can be identified by the use of forward-looking terminology, such as, "will", "to" or comparable terminology referring to future events or results. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors. See the Company's reports filed with the Toronto Stock Exchange, the B.C. and Ontario Securities Commissions, and the U.S. Securities and Exchange Commission from time to time for cautionary statements identifying other important factors with respect to such forward-looking statements, including certain risks and uncertainties, that could cause actual results to differ materially from results referred to in forward-looking statements. The Company assumes no obligation to update the information contained in this press release.*